API | ripretinib

ripretinib (Qinlock) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Fast Track ^FDA Breakthrough Therapy ^FDA Priority Review ^FDA

AACT PubChem

Active Ingredient History

NOW

Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Mast/stem cell growth factor receptor Kit (Mus musculus) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Drug Pricing (per unit)

United States

$263.8939 - $350.1954

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

dcc-2618

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Gastrointestinal Stromal Tumors (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Gastrointestinal Stromal Tumors (Phase 3)

Intestinal Neoplasms (Phase 2)

Mastocytosis (Phase 1)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue